SCHEMBL14937992

SCHEMBL14937992

Cn1ncc(C#Cc2cccc(S(N)(=O)=O)c2)c1-c1cnn(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.46
FLT3 P36888 1/20 0.46
PTGS2 P35354 5/20 0.39
CA9 Q16790 7/20 0.39
CA12 O43570 6/20 0.39
CA2 P00918 6/20 0.39
CA1 P00915 5/20 0.39
ALOX5 P09917 1/20 0.37
PTGS1 P23219 2/20 0.36
CYP2C9 P11712 1/20 0.35
PDPK1 O15530 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14938283 0.90 CA2 (0.46) NTRK1FLT3PTGS2CA9CA12
SCHEMBL14937664 0.89 PTGS2 (0.46) NTRK1FLT3PTGS2CA9CA12
SCHEMBL14938170 0.89 CA9 (0.44) PTGS2CA9CA12CA2CA1
SCHEMBL14938099 0.84 CA12 (0.44) PTGS2CA9CA12CA2CA1
SCHEMBL14938256 0.81 CA12 (0.42) PTGS2CA9CA12CA2CA1
SCHEMBL14938233 0.81 CA1 (0.45) CA9CA12CA2CA1CA13
SCHEMBL14938231 0.80 PTGS2 (0.40) PTGS2PTGDR2
SCHEMBL14937938 0.80 PTGS2 (0.40) PTGS2CA9CA12CA2CA1
SCHEMBL14938258 0.80 CA12 (0.46) PTGS2CA9CA12CA2CA1
SCHEMBL14938021 0.79 KDM4E (0.43) CA9CA12CA2CA1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
EP-2599775-A1 ETHINYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE GABRE, GRIN3A, GRIK5 NTRK1 2216/4885FLT3 2592/4885PTGS2 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.